Singh Puneet, Lim Bora
Division of Surgery, Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Breast Oncology, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Curr Oncol Rep. 2022 Mar;24(3):273-284. doi: 10.1007/s11912-022-01199-y. Epub 2022 Feb 3.
Apoptosis is a major mechanism of cancer cell death. Thus, evasion of apoptosis results in therapy resistance. Here, we review apoptosis modulators in cancer and their recent developments, including MDM2 inhibitors and kinase inhibitors that can induce effective apoptosis.
Both extrinsic pathways (external stimuli through cell surface death receptor) and intrinsic pathways (mitochondrial-mediated regulation upon genotoxic stress) regulate the complex process of apoptosis through orchestration of various proteins such as members of the BCL-2 family. Dysregulation within these complex steps can result in evasion of apoptosis. However, via the combined evolution of medicinal chemistry and molecular biology, omics assays have led to innovative inducers of apoptosis and inhibitors of anti-apoptotic regulators. Many of these agents are now being tested in cancer patients in early-phase trials. We believe that despite a sluggish speed of development, apoptosis targeting holds promise as a relevant strategy in cancer therapeutics.
细胞凋亡是癌细胞死亡的主要机制。因此,逃避细胞凋亡会导致治疗耐药性。在此,我们综述癌症中的细胞凋亡调节剂及其最新进展,包括可诱导有效细胞凋亡的MDM2抑制剂和激酶抑制剂。
外在途径(通过细胞表面死亡受体的外部刺激)和内在途径(在基因毒性应激下线粒体介导的调节)通过协调各种蛋白质(如BCL-2家族成员)来调节细胞凋亡的复杂过程。这些复杂步骤中的失调可导致逃避细胞凋亡。然而,通过药物化学和分子生物学的联合发展,组学分析已带来了创新的细胞凋亡诱导剂和抗凋亡调节因子抑制剂。其中许多药物目前正在癌症患者中进行早期试验测试。我们认为,尽管开发速度缓慢,但靶向细胞凋亡作为癌症治疗的一种相关策略仍具有前景。